Galena Biopharma Company Profile (NASDAQ:GALE)

About Galena Biopharma

Galena Biopharma logoGalena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GALE
  • CUSIP:
Key Metrics:
  • Previous Close: $0.69
  • 50 Day Moving Average: $1.372
  • 200 Day Moving Average: $1.191
  • 52-Week Range: $0.62 - $49.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.39
  • P/E Growth: 0.000
  • Market Cap: $7.46M
  • Outstanding Shares: 10,850,000
  • Beta: 2.72
Profitability:
  • Return on Equity: -115.12%
  • Return on Assets: -27.37%
Debt:
  • Current Ratio: 1.05%
  • Quick Ratio: 1.05%
Additional Links:
Companies Related to Galena Biopharma:

Analyst Ratings

Consensus Ratings for Galena Biopharma (NASDAQ:GALE) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $3.37 (389.53% upside)

Analysts' Ratings History for Galena Biopharma (NASDAQ:GALE)
Show:
DateFirmActionRatingPrice TargetDetails
2/6/2017FBR & CoDowngradeOutperform -> Market Perform$11.00 -> $4.00View Rating Details
2/2/2017Maxim GroupDowngradeBuy -> HoldView Rating Details
9/20/2016S&P Equity ResearchLower Price Target$0.39 -> $0.34View Rating Details
6/29/2016Noble FinancialDowngradeBuy -> HoldView Rating Details
6/29/2016Raymond James Financial, Inc.DowngradeOutperform -> Market PerformView Rating Details
6/9/2016Roth CapitalReiterated RatingBuy$5.00View Rating Details
1/22/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$4.00View Rating Details
12/8/2015Cantor FitzgeraldUpgradeSell -> Hold$2.00View Rating Details
8/7/2015MLV & Co.Reiterated RatingBuy$5.00View Rating Details
3/6/2015Needham & Company LLCSet Price TargetBuy$7.00 -> $4.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Galena Biopharma (NASDAQ:GALE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/9/2016Q3 2016($0.05)($0.02)ViewListenView Earnings Details
8/9/2016Q216($0.06)$0.05ViewN/AView Earnings Details
5/10/2016Q1($0.06)($0.07)ViewListenView Earnings Details
3/10/2016Q4($0.05)($0.07)$2.61 millionViewListenView Earnings Details
11/9/2015Q315($0.07)($0.11)$4.22 millionViewListenView Earnings Details
8/6/2015Q215($0.09)($0.10)$3.54 million$3.38 millionViewN/AView Earnings Details
5/7/2015Q115($0.09)($0.08)$3.47 million$2.75 millionViewListenView Earnings Details
3/5/2015Q414($0.11)($0.06)$2.58 million$3.20 millionViewN/AView Earnings Details
11/3/2014Q314($0.11)($0.05)$2.66 million$1.60 millionViewN/AView Earnings Details
8/11/2014Q214($0.09)($0.17)$2.99 million$2.30 millionViewN/AView Earnings Details
5/6/2014Q1($0.10)($0.02)$2.09 million$2.17 millionViewN/AView Earnings Details
3/17/2014Q413($0.09)($0.46)$1.62 million$1.32 millionViewN/AView Earnings Details
8/8/2013Q213($0.10)($0.11)ViewN/AView Earnings Details
3/12/2013Q4 2012($0.62)($0.53)ViewN/AView Earnings Details
11/13/2012Q312($0.09)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Galena Biopharma (NASDAQ:GALE)
Current Year EPS Consensus Estimate: $-2.590 EPS
Next Year EPS Consensus Estimate: $-1.750 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.05)($0.05)($0.05)
Q2 20161($0.08)($0.08)($0.08)
Q3 20161($0.04)($0.04)($0.04)
Q4 20162($0.06)($0.03)($0.05)
Q1 20171($0.98)($0.98)($0.98)
Q2 20171($0.94)($0.94)($0.94)
Q3 20171($0.50)($0.50)($0.50)
Q4 20171($0.34)($0.34)($0.34)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Galena Biopharma (NASDAQ:GALE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galena Biopharma (NASDAQ:GALE)
Insider Ownership Percentage: 2.02%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/8/2017Hudson Bay Capital ManagementMajor ShareholderSell2,363,441$0.84$1,985,290.44View SEC Filing  
2/12/2014Richard ChinDirectorSell187,500$4.33$811,875.00View SEC Filing  
2/7/2014Rudolph NisiDirectorBuy20,000$4.94$98,800.00View SEC Filing  
1/30/2014Mark SchwartzCOOSell100,000$5.57$557,000.00View SEC Filing  
1/30/2014Sanford HillsbergDirectorSell250,000$5.41$1,352,500.00View SEC Filing  
1/29/2014Rudolph NisiDirectorSell250,000$5.28$1,320,000.00View SEC Filing  
1/22/2014Steven KriegsmanDirectorSell450,000$6.52$2,934,000.00View SEC Filing  
1/17/2014Rudolph NisiDirectorSell200,000$6.90$1,380,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Galena Biopharma (NASDAQ:GALE)
DateHeadline
einnews.com logoEast Texas Girl Scouts earn World Day of Thinking patch at international fair (NASDAQ:GALE)
brazilbusiness.einnews.com - February 25 at 10:12 PM
einnews.com logoNo. 12 Gill St. Bernard's wins 3rd straight SCT title -- FULL COVERAGE (NASDAQ:GALE)
semiconductors.einnews.com - February 25 at 10:12 PM
einnews.com logoSamad Seyidov: "Such provocations - traditional, usual tactics of Armenians" (NASDAQ:GALE)
world.einnews.com - February 25 at 10:12 PM
einnews.com logoPolice: Car plows into parade crowd in New Orleans; 12 hurt (NASDAQ:GALE)
it.einnews.com - February 25 at 10:12 PM
einnews.com logoCzech Republic Has No Info on 'Specific Threat' to North Korean Leader's Uncle (NASDAQ:GALE)
ethanol.einnews.com - February 25 at 5:11 PM
einnews.com logo1 Dead, 1 Critical In LoDo Shooting (NASDAQ:GALE)
world.einnews.com - February 25 at 5:11 PM
einnews.com logoAberdeen 1 Ross County 0 as Adam Rooney goal moves the Dons nine clear of Rangers (NASDAQ:GALE)
brazilbusiness.einnews.com - February 25 at 5:11 PM
4-traders.com logoLaw Offices of Howard G. Smith Commences Investigation on Behalf of Galena Biopharma, Inc. Investors (NASDAQ:GALE)
www.4-traders.com - February 24 at 6:38 PM
finance.yahoo.com logoIMPORTANT GALENA BIOPHARMA, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the District of New Jersey against Galena Biopharma, Inc. (NASDAQ:GALE)
finance.yahoo.com - February 24 at 6:38 PM
News IconLawsuit for Investors in shares of Galena Biopharma Inc (NASDAQ ... - GroundReport (NASDAQ:GALE)
www.groundreport.com - February 24 at 11:07 AM
News IconGalena Biopharma Inc (NASDAQ:GALE) Appoints Stephen F. Ghiglieri In A Bid To Foster Development - Traders350 (NASDAQ:GALE)
traders350.com - February 24 at 11:07 AM
News IconGalena Biopharma appoints interim CEO (NASDAQ:GALE)
www.poandpo.com - February 23 at 5:20 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Galena Biopharma, Inc. (GALE) and Lead Plaintiff Deadline: April 14, 2017 (NASDAQ:GALE)
us.rd.yahoo.com - February 23 at 5:20 PM
businesswire.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena ... - Business Wire (press release) (NASDAQ:GALE)
www.businesswire.com - February 23 at 3:38 AM
marketexclusive.com logoGALENA BIOPHARMA, INC. (NASDAQ:GALE) Files An 8-K Departure of Directors or Certain Officers; Election of ... - Market Exclusive (NASDAQ:GALE)
marketexclusive.com - February 23 at 3:38 AM
4-traders.com logoKhang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma Inc., and Encourages Investors with Losses to Contact the Firm (NASDAQ:GALE)
www.4-traders.com - February 22 at 10:37 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Galena Biopharma Inc., and Encourages Investors with Losses to Contact the Firm (NASDAQ:GALE)
finance.yahoo.com - February 22 at 10:37 PM
4-traders.com logoGalena Biopharma : Board of Directors Appoints Stephen F.Ghiglieri as Interim Chief Executive Officer (NASDAQ:GALE)
www.4-traders.com - February 22 at 5:35 PM
finance.yahoo.com logoInvestor Alert: Kaplan Fox Announces Investigation Of Galena Biopharma Inc. (NASDAQ:GALE)
finance.yahoo.com - February 22 at 5:35 PM
4-traders.com logoGalena Biopharma Inc: Stephen F. Ghiglieri Has Been Appointed Interim CEO (NASDAQ:GALE)
www.4-traders.com - February 22 at 11:29 AM
streetinsider.com logoGalena Biopharma (GALE) Names Stephen Ghiglieri as Interim CEO (NASDAQ:GALE)
www.streetinsider.com - February 22 at 11:29 AM
reuters.com logoBRIEF-Galena Biopharma board appoints Stephen Ghiglieri as interim CEO (NASDAQ:GALE)
www.reuters.com - February 22 at 11:29 AM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:GALE)
us.rd.yahoo.com - February 22 at 11:29 AM
finance.yahoo.com logoGalena Biopharma Board of Directors Appoints Stephen F. Ghiglieri as Interim Chief Executive Officer (NASDAQ:GALE)
finance.yahoo.com - February 22 at 11:29 AM
finance.yahoo.com logo4:11 pm Galena Biopharma appoints CFO Stephen F. Ghiglieri as Interim CEO (NASDAQ:GALE)
finance.yahoo.com - February 22 at 11:29 AM
biz.yahoo.com logoGALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibi (NASDAQ:GALE)
biz.yahoo.com - February 22 at 11:29 AM
tmcnet.com logoGALE FRAUD NOTICE: Rosen Law Firm Reminds Galena Biopharma, Inc. Investors of Important Deadline in Class Action - GALE (NASDAQ:GALE)
www.tmcnet.com - February 20 at 4:54 PM
finance.yahoo.com logoGALE FRAUD NOTICE: Rosen Law Firm Reminds Galena Biopharma, Inc. Investors of Important Deadline in Class Action – GALE (NASDAQ:GALE)
finance.yahoo.com - February 20 at 4:54 PM
News IconGalena Biopharma, Inc. (NASDAQ:GALE) Quarterly EPS At $-0.47 - Stock Observer (NASDAQ:GALE)
www.thestockobserver.com - February 19 at 10:40 AM
reuters.com logoBRIEF-CVI Investments reports 9.3 pct passive stake in Galena Biopharma (NASDAQ:GALE)
uk.reuters.com - February 17 at 3:55 PM
News IconThe Galena Biopharma, Inc. (GALE) Rating Reiterate by the Maxim Group (NASDAQ:GALE)
www.graffiotech.com - February 17 at 8:46 AM
News IconGlancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Galena BioPharma, Inc. (NASDAQ:GALE)
www.cbs58.com - February 16 at 5:17 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Galena … (NASDAQ:GALE)
finance.yahoo.com - February 16 at 5:17 PM
4-traders.com logoGoldberg Law PC Announces Securities Class Action Lawsuit against Galena Biopharma Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:GALE)
www.4-traders.com - February 16 at 5:17 PM
us.rd.yahoo.com logoINVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Galena Biopharma Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:GALE)
us.rd.yahoo.com - February 16 at 5:17 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Galena Biopharma, Inc. (GALE) To Contact Brower Piven Before The Lead Plaintiff Deadlin (NASDAQ:GALE)
us.rd.yahoo.com - February 16 at 5:17 PM
us.rd.yahoo.com logoCORRECTING and REPLACING Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Galena Biopharma, Inc. (NASDAQ:GALE)
us.rd.yahoo.com - February 16 at 5:17 PM
us.rd.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Galena Biopharma Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:GALE)
us.rd.yahoo.com - February 16 at 5:17 PM
finance.yahoo.com logoThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Galena Biopharma, Inc. Investors and Encourages Investors to Contact the Firm (NASDAQ:GALE)
finance.yahoo.com - February 16 at 5:17 PM
feeds.benzinga.com logoSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Galena Biopharma, Inc. (GALE) To Contact Brower Piven Before The Lead Plaintiff Deadline (NASDAQ:GALE)
feeds.benzinga.com - February 16 at 12:26 AM
News IconGalena Biopharma, Inc. (NASDAQ:GALE) Earns 4 Analysts Hold Rating (NASDAQ:GALE)
latribunadecanarias.com - February 14 at 6:30 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Galena Biopharma Inc., and Encourages Investors with Losses to Contact the Firm (NASDAQ:GALE)
finance.yahoo.com - February 14 at 6:29 PM
finance.yahoo.com logoRobbins Arroyo LLP: Galena Biopharma, Inc. (GALE) Misled Shareholders According to a Recently Filed Class Action (NASDAQ:GALE)
finance.yahoo.com - February 14 at 6:29 PM
finance.yahoo.com logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Galena Biopharma, Inc. Investors (NASDAQ:GALE)
finance.yahoo.com - February 13 at 6:11 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Galena Biopharma, Inc. (GALE) & Lead Plaintiff Deadline: April 14, 2017 (NASDAQ:GALE)
finance.yahoo.com - February 13 at 6:11 PM
finance.yahoo.com logoGalena Biopharma Announces Closing of Public Offering of Common Stock and Warrants (NASDAQ:GALE)
finance.yahoo.com - February 13 at 6:11 PM
4-traders.com logoRosen Law Firm Files Securities Class Action Lawsuit Against Galena Biopharma, Inc. (NASDAQ:GALE)
www.4-traders.com - February 13 at 11:22 AM
finance.yahoo.com logoEQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Galena Biopharma, Inc. (NASDAQ:GALE)
finance.yahoo.com - February 13 at 11:22 AM
prnewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Galena Biopharma, Inc ... - PR Newswire (press release) (NASDAQ:GALE)
www.prnewswire.com - February 12 at 5:14 PM
businesswire.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Galena Biopharma Inc. and ... - Business Wire (press release) (NASDAQ:GALE)
www.businesswire.com - February 12 at 5:14 PM

Social

What is Galena Biopharma's stock symbol?

Galena Biopharma trades on the NASDAQ under the ticker symbol "GALE."

Where is Galena Biopharma's stock going? Where will Galena Biopharma's stock price be in 2017?

5 brokers have issued 1-year target prices for Galena Biopharma's shares. Their predictions range from $0.34 to $5.00. On average, they expect Galena Biopharma's stock price to reach $3.37 in the next twelve months.

When will Galena Biopharma announce their earnings?

Galena Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

What are analysts saying about Galena Biopharma stock?

Here are some recent quotes from research analysts about Galena Biopharma stock:

  • FBR & Co analysts commented, "On January 31, Galena Biopharma announced that Mark W. Schwartz, Ph.D., resigned as the company's president, CEO, and member of the board of directors, effective immediately. An interim CEO, who will oversee Galena as it explores strategic alternatives with assistance from an independent advisory firm, is expected to be appointed in the next several weeks. At this point, it is not certain whether Galena will continue clinical development of its pipeline on its own, outlicense its assets, or undergo restructuring of its corporate operations before a final decision is made in 2H17. We believe the high value of Galena's pipeline assets remains under-appreciated; however, due to near-term uncertainty, we are moving to the sidelines and lowering our rating from Outperform to Market Perform with a new price target of $4 versus our previous $11 price target." (2/6/2017)
  • According to Zacks Investment Research, "Galena Biopharma, Inc. is a biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. Galena Biopharma, Inc., formally known as RXi Pharmaceuticals Corporation, is based in Portland, Oregon. " (12/6/2016)

Who owns Galena Biopharma stock?

Galena Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (1.32%).

Who sold Galena Biopharma stock? Who is selling Galena Biopharma stock?

Galena Biopharma's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp.

How do I buy Galena Biopharma stock?

Shares of Galena Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Galena Biopharma stock cost?

One share of Galena Biopharma stock can currently be purchased for approximately $0.69.

Galena Biopharma (NASDAQ:GALE) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Galena Biopharma (NASDAQ:GALE)

Earnings History Chart

Earnings by Quarter for Galena Biopharma (NASDAQ:GALE)

Dividend History Chart

Dividend Payments by Quarter for Galena Biopharma (NASDAQ:GALE)

Last Updated on 2/25/2017 by MarketBeat.com Staff